A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

Table 3 EU-COVAT-1-AGED – time schedule

First patient first visit (FPFV)	November 2021
Last patient first visit (LPFV)	September 2022
Last patient last visit (LPLV)	September 2023
Analysis	October 2022 (Primary endpoint analysis)
End of study definition	The end of study will be on the day of database lock.
End of trial	November 2023
Final study report	December 2023

ISSN: 1745-6215